JP2016512693A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512693A5
JP2016512693A5 JP2016503010A JP2016503010A JP2016512693A5 JP 2016512693 A5 JP2016512693 A5 JP 2016512693A5 JP 2016503010 A JP2016503010 A JP 2016503010A JP 2016503010 A JP2016503010 A JP 2016503010A JP 2016512693 A5 JP2016512693 A5 JP 2016512693A5
Authority
JP
Japan
Prior art keywords
reagent
providing
cell
tissue sample
chaotrope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503010A
Other languages
English (en)
Japanese (ja)
Other versions
JP6465857B2 (ja
JP2016512693A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029198 external-priority patent/WO2014144682A1/en
Publication of JP2016512693A publication Critical patent/JP2016512693A/ja
Publication of JP2016512693A5 publication Critical patent/JP2016512693A5/ja
Application granted granted Critical
Publication of JP6465857B2 publication Critical patent/JP6465857B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503010A 2013-03-15 2014-03-14 外科的に摘出された組織における癌細胞の生存能を維持するための方法および試薬 Active JP6465857B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798627P 2013-03-15 2013-03-15
US61/798,627 2013-03-15
PCT/US2014/029198 WO2014144682A1 (en) 2013-03-15 2014-03-14 Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue

Publications (3)

Publication Number Publication Date
JP2016512693A JP2016512693A (ja) 2016-05-09
JP2016512693A5 true JP2016512693A5 (enExample) 2017-04-13
JP6465857B2 JP6465857B2 (ja) 2019-02-06

Family

ID=51528685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503010A Active JP6465857B2 (ja) 2013-03-15 2014-03-14 外科的に摘出された組織における癌細胞の生存能を維持するための方法および試薬

Country Status (17)

Country Link
US (5) US9113623B2 (enExample)
EP (2) EP3581643A1 (enExample)
JP (1) JP6465857B2 (enExample)
CN (2) CN105121629B (enExample)
CA (1) CA2941929C (enExample)
CY (1) CY1120801T1 (enExample)
DK (1) DK2970878T3 (enExample)
ES (1) ES2684582T3 (enExample)
HR (1) HRP20181352T1 (enExample)
HU (1) HUE039933T2 (enExample)
LT (1) LT2970878T (enExample)
PL (1) PL2970878T3 (enExample)
PT (1) PT2970878T (enExample)
RS (1) RS57900B1 (enExample)
SI (1) SI2970878T1 (enExample)
SM (1) SMT201800457T1 (enExample)
WO (1) WO2014144682A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121629B (zh) 2013-03-15 2020-12-18 特拉基应用基因组学有限责任公司 用于保持已手术去除的组织中的癌细胞活力的方法和试剂
US10053676B2 (en) 2014-11-25 2018-08-21 Bio-Rad Laboratories, Inc. Arginine improves polymerase storage stability
CN107333750A (zh) * 2017-06-11 2017-11-10 成都吱吖科技有限公司 一种长时血液细胞稳定剂
WO2021055170A1 (en) * 2019-09-17 2021-03-25 Longhorn Vaccines And Diagnostics, Llc Multipurpose compositions for collecting and transporting biological material
WO2022010916A1 (en) * 2020-07-07 2022-01-13 Truckee Applied Genomics, Llc Cell preservation reagents and methods of use
CN117063915B (zh) * 2023-08-17 2026-02-24 镜像绮点(上海)细胞技术有限公司 原代肿瘤细胞冻存液

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409826A (en) * 1993-06-08 1995-04-25 Coulter Corporation Preserved, non-infectious control cells prepared by the modulation or modification of normal cells
JP2000509018A (ja) * 1996-03-26 2000-07-18 イーライ・リリー・アンド・カンパニー 肥満タンパク質製剤
US20010007673A1 (en) 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
JP2001526051A (ja) 1997-12-10 2001-12-18 シエラ ダイアグノスティクス，インク． 体液中のｄｎａを保存するための方法及び試薬
US20080064108A1 (en) 1997-12-10 2008-03-13 Tony Baker Urine Preservation System
US7569342B2 (en) 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
CN1230524C (zh) * 2000-12-04 2005-12-07 株式会社淋巴技术 细胞保存液和使用该保存液的细胞保存方法
KR20020066778A (ko) 2001-02-13 2002-08-21 한국과학기술연구원 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
WO2008111981A1 (en) 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation of macromolecules
AU2003300899A1 (en) * 2002-12-12 2004-06-30 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
US8793895B2 (en) * 2006-02-10 2014-08-05 Praxair Technology, Inc. Lyophilization system and method
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
CN101617045A (zh) 2006-09-12 2009-12-30 谢拉分子公司 使用离液剂的缓冲溶液去除核酸的分子分析干扰物
US8652782B2 (en) * 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
EP2086622A2 (en) 2006-10-27 2009-08-12 Sierra Molecular Corporation Penetratable septum cap
WO2008071384A1 (en) 2006-12-13 2008-06-19 Roche Diagnostics Gmbh Use of tde for the isolation of nucleic acids
CA2680801A1 (en) 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilizationof a cell and/or macromolecule
AU2008321382A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2010003037A2 (en) * 2008-07-03 2010-01-07 Sierra Molecular Corporation Compositions, systems, and methods for stabilization of a cell and/or macromolecule
WO2010028156A2 (en) 2008-09-04 2010-03-11 Board Of Regents, The University Of Texas System Dual modality detection of apoptosis
US9133343B2 (en) * 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
CN102318597B (zh) * 2011-08-19 2013-04-03 张雪云 一种液基细胞保存液组合物及其制备方法
CN105121629B (zh) 2013-03-15 2020-12-18 特拉基应用基因组学有限责任公司 用于保持已手术去除的组织中的癌细胞活力的方法和试剂

Similar Documents

Publication Publication Date Title
PL3313991T3 (pl) Modyfikowany czynnik ix oraz kompozycje, sposoby i zastosowania do transferu genów do komórek, narządów i tkanek
BR112015017405A2 (pt) composições que incluem agentes hidrofobizantes e estabilizantes e métodos para preparação e utilização das mesmas
EP3310931A4 (en) CRISPR / CAS9 COMPLEX FOR INTRODUCING A FUNCTIONAL POLYPEPTIDE IN CELLS OF A BLOOD CELL LINE
EP4265250A3 (en) Solid forms of an ask1 inhibitor
JP2016520647A5 (enExample)
MX2016010266A (es) Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
EP3564356A4 (en) SOLUTION FOR THE CRYCON PRESERVATION OF ANIMAL CELLS OR ANIMAL TISSUE, CRYCON PRESERVED PRODUCT AND METHOD FOR THE CRYCON PRESERVATION
BR112015021189A2 (pt) métodos de banco de células de alta densidade
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
SI2958913T1 (sl) Sfingozin-1-fosfat receptor agonisti, postopki za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo kot aktivno sredstvo
MX375911B (es) Constructos de anticuerpo multiespecifico.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
IL280962A (en) Methods for delivering gene editing reagents to cells within organs
EP3202885A4 (en) Novel biological activity testing structure for tracking single cell, using gelling agents
DK3232780T3 (da) Vandige adjuvans-sammensætninger, der indeholder elektrolyt, sammensætninger, som indeholder et aktivt stof, og anvendelse deraf
MX2013006188A (es) Agentes de generacion de imagenes pet de apoptosis.
BR112013021784A2 (pt) composição de reagente, e, método para a recuperação de um metal de uma solução aquosa
MX389168B (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
EP3727585C0 (en) SYSTEM FOR INDUCING SONOPERMEABILIZATION TRANSFER OF A DRUG INTO CANCER CELLS
WO2014144682A4 (en) Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue
CL2015002065A1 (es) Método para mejorar composiciones de sal de nitrato por medio de ácido nítrico para su uso con medio de transferencia de calor o medio de almacenamiento de calor.
PT3265579T (pt) Processo não radioativo de determinação da ação citolítica de um agente face a células-alvo, sua utilização e kit associado
NZ727749A (en) Use of anti-aging glycopeptides to enhance beta cell health, survival and improve transplant outcome
EP2692772A4 (en) POLYETHERIC COMPOUND AND ELECTROLYTE COMPOSITION
BR112014028748A2 (pt) método, para estabilizar e para preservar uma oxidase do ácido ascórbico, e, composição estabilizada de uma oxidase do ácido ascórbico.